Alvotech

NASDAQ:ALVO

Drug Manufacturers - Specialty & Generic

Healthcare
$4.55 -1.02%

-$0.04 today

Market cap
$1.62B
Beta
0.21
P/E (TTM)
-15.9
EPS (TTM)
-$0.24
52W Low $2.94High $9.94

Volume 1.56M

Average 0.65M

ALVO Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

AlvotechNASDAQ: ALVO

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 89.0% from a year ago

Deferred revenue stood at $9.55M at the end of Q1 FY2026, down 89.0% from a year earlier and down 68.6% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.

Context

  • Deferred revenue amounted to 0.7% of total assets at the end of Q1 FY2026, down 6.3 pp from a year earlier.
  • Deferred revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -89.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.55M-68.6% QoQ
Last fiscal yearDec 2025
$30.36M+90.0% YoY
Year agoMar 2025
$87M-89.0% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.0%——
1 year+90.0%——
3-year CAGR-6.3%——
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
30.36M USD
Year-over-year change
+90.0%
4-year CAGR
+0.6%

Deferred Revenue vs competitors

How ALVO compares with its peers on the latest reported figures

  • ALVO's Mar 2026 deferred revenue of $9.55M is the 2nd highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -89.0% is the 2nd highest of 5, against a peer median of -96.7%.
  • Deferred revenue amounts to 0.7% of total assets for ALVO, versus a peer median of 0.0%.
ALVO Competitors Peer median
Deferred Revenue for ALVO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$220.4M -54.3%+5.0%0.5%
ALVOAlvotechMar 2026$9.55M -89.0%-6.3%0.7%
COLLCollegium Pharmaceutical, Inc.Mar 2026$667K -93.3%—0.0%
AMGNAmgen Inc.Jun 2026$0 ——0.0%
TEVATeva Pharmaceutical Industries LimitedJun 2026$0 ——0.0%
BIIBBiogen Inc.Jun 2026$0 ——0.0%
AMRXAmneal Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
OGNOrganon & Co.Sep 2026$0 ——0.0%
ETONEton Pharmaceuticals, Inc.Mar 2026$0 -100.0%—0.0%
AMPHAmphastar Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
HROWHarrow Health, Inc.Mar 2026$0 -100.0%+91.1%0.0%
Peer median (excluding ALVO) $0-96.7%+48.0%0.0%

Competitors are the stored peer set for ALVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents17.56M66.43M11.16M51.43M172.36M
Short-term Investments00000
Net Receivables53.88M71.39M87.22M251.72M153.79M
Inventory39.06M71.47M74.43M127.89M220.05M
Other Current Assets0851K000
Total Current Assets119.82M230.74M194.84M455.02M574.02M
Property, Plant & Equipment (Net)205.33M268.1M356.58M409.74M356.4M
Goodwill12.37M11.64M12.06M11.33M12.84M
Intangible Assets21.51M25.65M19.08M20.62M81.83M
Long-term Investments55.31M48.57M18.49M22.71M122.93M
Tax Assets170.42M209.5M309.81M298.36M192.21M
Other Non-current Assets13.23M34.25M39.23M3.62M146.87M
Total Non-current Assets478.16M597.71M755.25M766.38M913.08M
Total Assets597.98M828.44M950.09M1.22B1.49B
Account Payables28.59M49.19M80.56M67.13M126.12M
Short-term Debt2.77M19.92M38.03M32.7M36.92M
Tax Payables841K934K925K204K1.04M
Deferred Revenue29.69M36.92M59.18M15.98M30.36M
Other Current Liabilities5.26M17.46M34.5M6.63M13.7M
Total Current Liabilities111.84M167.29M260.95M193.4M304.08M
Long-term Debt398.14M744.65M922.13M1.04B1.26B
Deferred Tax Liabilities150K309K53K1.81M7.87M
Deferred Revenue (Non-current)44.84M57.02M73.26M80.72M5.5M
Other Non-current Liabilities63.77M388.22M520.55M210.22M53.99M
Total Non-current Liabilities621.75M1.23B1.62B1.44B1.47B
Total Liabilities733.59M1.39B1.88B1.63B1.77B
Common Stock135K2.13M2.28M2.83M2.93M
Retained Earnings(1.14B)(1.65B)(2.21B)(2.44B)(2.41B)
Accumulated OCI4.67M29.14M41.38M15.05M16.68M
Other Stockholders Equity00000
Minority Interest00000
Total Equity(135.61M)(564.42M)(932.49M)(412.77M)(284.49M)
Total Debt523.05M805.1M1.08B1.19B1.45B
Net Debt505.5M738.68M1.06B1.14B1.28B

Alvotech

NASDAQ:ALVO

Intrinsic Alpha fair value

Locked

Current Price

$4.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.